Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ibandronate, Capecitabine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs |
| B | EXPERIMENTAL | Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6 |
| Name | Type | Description |
|---|---|---|
| Ibandronate, Capecitabine | DRUG | Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6 |
| Ibandronate | DRUG | Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs |
Inclusion Criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements. 2. Histologically confirmed unilateral or ...
Top 20 of 82 competitors